%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
108 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T20:00:52Z
2024-03-29T01:30:14-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T01:30:14-07:00
application/pdf
Heather
2001-964.dec02
uuid:b8994572-1dd1-11b2-0a00-7a0927edca00
uuid:b8994575-1dd1-11b2-0a00-380000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
131 0 obj
[135 0 R]
endobj
132 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.1109 Tw 10 0 0 10 54 713.1616 Tm
(trimester IVCY)Tj
/TT1 1 Tf
0 Tc 0.11079 Tw 6.6819 0 Td
[(in uter)36.9 (o)]TJ
/TT0 1 Tf
3.5733 0 Td
(exposure ended in live birth with)Tj
-0.0218 Tw -10.2552 -1.2 Td
(multiple anomalies)Tj
0 Tw 6.5 0 0 6.5 130.1516 704.4615 Tm
(15,17)Tj
-0.0218 Tw 10 0 0 10 144.7765 701.1616 Tm
(. In the first case, the mother received)Tj
0.00259 Tw -9.0777 -1.2 Td
[(200 mg IVCY)-215.8 (on days 15 and 46 of gestational age)]TJ
0 Tw 6.5 0 0 6.5 259.4021 692.4615 Tm
(17)Tj
0.00259 Tw 10 0 0 10 265.902 689.1616 Tm
(. In the)Tj
-0.0343 Tw -21.1902 -1.2 Td
[(second case, the mother received 20 mg/kg IVCY)-178.8 (on day 37.)]TJ
0.2625 Tw 0 -1.2 TD
[(Congenital anomalies were similar)39.8 (, consisting of micro-)]TJ
0.01331 Tc 0.36169 Tw T*
[(cephaly)64.9 (, malformations of ears and eyes, hypoplastic)]TJ
0 Tc 0.2814 Tw T*
(thumbs, suggesting a distinct embryopathy)Tj
0 Tw 6.5 0 0 6.5 236.619 644.4615 Tm
(15)Tj
-0.00011 Tc 0.28149 Tw 10 0 0 10 243.119 641.1616 Tm
(. One preg-)Tj
0 Tc -0.03329 Tw -18.9119 -1.2 Td
[(nancy)64.9 (, which began 10 days after the last IVCY)-179.8 (pulse, ended)]TJ
0.1367 Tw T*
(in normal live birth)Tj
0 Tw 6.5 0 0 6.5 135.5825 620.4615 Tm
(16)Tj
0.1366 Tw 10 0 0 10 142.0824 617.1616 Tm
[(. Use of CY)-349.9 (in the second and third)]TJ
0.02499 Tw -8.8082 -1.2 Td
(trimesters seemed to be free of congenital anomalies)Tj
-0.00011 Tc 0 Tw 6.5 0 0 6.5 265.9234 608.4615 Tm
(18-21)Tj
0 Tc 10 0 0 10 281.0863 605.1616 Tm
(. )Tj
0.1778 Tw -22.7086 -1.2 Td
[(W)79.8 (e did not observe any case of congenital malformation)]TJ
-0.00011 Tc 0.1149 Tw T*
[(when pregnancy occurred after IVCY)-328 (therapy withdrawal.)]TJ
0 Tc 0.2291 Tw T*
[(The longterm ef)17.8 (fect of CY)-442.3 (on pregnancy is not known.)]TJ
-0.00011 Tc 0 Tw T*
(Ramsey-Goldman)Tj
0 Tc 6.5 0 0 6.5 126.7563 560.4615 Tm
(22)Tj
0.1617 Tw 10 0 0 10 137.3731 557.1616 Tm
(analyzed the outcome of 23 pregnan-)Tj
0.1494 Tw -8.3373 -1.2 Td
(cies occurring in women treated with immunosuppressive)Tj
0.00591 Tc 0.369 Tw T*
[(treatment \(CY)128.9 (, methotrexate, or azathioprine\) prior or)]TJ
0 Tc 0.02409 Tw T*
[(during pregnancy)64.9 (, and 1)36.9 (13 pregnancies with no exposure to)]TJ
0.0387 Tw T*
[(immunosuppressive therapy)65 (. )17.7 (The rate of adverse pregnancy)]TJ
0.27609 Tw T*
[(outcome \(premature delivery)64.9 (, growth restriction, sponta-)]TJ
0.0831 Tw T*
[(neous abortion\) was similar in the 2 groups. )17.8 (There was no)]TJ
0.06619 Tw T*
(congenital malformation in infants exposed to azathioprine)Tj
0.02499 Tw T*
[(during pregnancy)64.9 (.)]TJ
-0.00011 Tc 0.0701 Tw 1.2 -1.2 Td
(In conclusion, risk of ovarian failure correlates with the)Tj
0 Tc -0.0013 Tw -1.2 -1.2 Td
[(age at IVCY)-211.9 (initiation, and is independent of the underlying)]TJ
-0.00011 Tc 0.1174 Tw T*
(inflammatory disease. Pregnancy may occur during IVCY)Tj
0 Tc 0.106 Tw T*
[(therapy)64.9 (, and an ef)17.8 (ficient contraception is mandatory)64.9 (. )54.9 (After)]TJ
-0.00011 Tc 0.1416 Tw T*
[(IVCY)-354.8 (withdrawal, pregnancy is possible with a favorable)]TJ
0.02499 Tw T*
(outcome in two-thirds of the cases.)Tj
/TT2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0.02499 Tw 8 0 0 8 61 355.1616 Tm
[(1.)-875.1 (McDermott EM, Powell RJ. Incidence of ovarian failure in)]TJ
0 Tc 1.675 -1.25 Td
(systemic lupus erythematosus after treatment with pulse )Tj
0 -1.25 TD
[(cyclophosphamide. )54.9 (Ann Rheum Dis 1996;55:224-9.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Mok CC, Lau CS, )17.7 (W)79.7 (oon Sing )17.7 (W)79.7 (ong R. Risk factors for ovarian)]TJ
0 Tc 1.675 -1.25 Td
(failure in patients with systemic lupus erythematosus receiving)Tj
T*
[(cyclophosphamide therapy)64.9 (. )54.9 (Arthritis Rheum 1998;41:831-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Boumpas DT)73.9 (, )54.8 (Austin HA, )17.7 (V)111 (aughn EM, )36.8 (Y)100 (arboro CH, Klippel JH,)]TJ
0 Tc 1.675 -1.25 Td
(Balow JE. Risk of sustained amenorrhoea in patients with systemic)Tj
T*
(lupus erythematosus receiving intermittent pulse cyclophosphamide)Tj
T*
[(therapy)64.9 (. )54.9 (Ann Intern Med 1993;1)36.8 (19:366-9.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Langevitz P)110.7 (, Klein L, Pras M, Many )54.8 (A. )17.7 (The ef)17.7 (fect of)]TJ
0 Tc 1.675 -1.25 Td
(cyclophosphamide pulses on fertility in patients with lupus)Tj
T*
[(nephritis. )54.9 (Am J Reprod Immunol 1992;28:157-8.)]TJ
-1.675 -1.25 Td
[(5.)-875 (Guillevin L, Jarousse B, Lok C, et al. Longterm followup after)]TJ
1.675 -1.25 Td
[(treatment of polyarteritis nodosa and Chur)17.8 (g Strauss angiitis with)]TJ
T*
(comparison of steroids, plasma exchange and cyclophosphamide to)Tj
T*
[(steroids and plasma exchange. )54.9 (A)-219.8 (prospective randomized trial of 71)]TJ
T*
(patients. J Rheumatol 1991;18:567-74.)Tj
-1.675 -1.25 Td
[(6.)-875 (Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse )]TJ
1.675 -1.25 Td
(administration of cyclophosphamide versus daily oral treatment in)Tj
33 68.671 Td
(patients with antineutrophil cytoplasmic antibody-associated)Tj
T*
[(vasculitis and renal involvement: a prospective, randomized study)64.9 (.)]TJ
T*
(Arthritis Rheum 1998;41:1835-44.)Tj
-1.675 -1.25 Td
[(7.)-875 (Guillevin L, Cordier JF)79.8 (, Lhote F)79.8 (, et al. )54.8 (A)-219.8 (prospective, multicenter)39.8 (,)]TJ
1.675 -1.25 Td
(randomized trial comparing steroids and pulse cyclophosphamide)Tj
T*
(versus steroids and oral cyclophosphamide in the treatment of)Tj
-0.00011 Tc T*
[(generalized )17.7 (W)79.7 (egener)-37 (\222)55.1 (s granulomatosis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;40:2187-98.)Tj
0.0249 Tw -1.675 -1.25 Td
[(8.)-875 (Falsetti L, Scalchi S, )17.7 (V)60.1 (illani MT)74 (, Bugari G. Premature ovarian)]TJ
1.675 -1.25 Td
(failure. Gynecol Endocrinol 1999;13:189-95.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Pasoto SG, )17.7 (V)60 (iana BST)73.9 (, Mendonca BB, )36.8 (Y)100 (oshinari NH, Bonfa H.)]TJ
0 Tc 1.675 -1.25 Td
(Anti-corpus luteum antibody: a novel serological marker for)Tj
T*
(ovarian dysfunction in systemic lupus erythematosus? J Rheumatol)Tj
0 Tw T*
(1999;26:1087-93.)Tj
0.02499 Tw -2.175 -1.25 Td
[(10.)-875 (Chapman RM, Sutclif)17.8 (fe SB. Protection of ovarian function by oral)]TJ
2.175 -1.25 Td
[(contraceptives in women receiving chemotherapy for Hodgkin\222)54.9 (s)]TJ
T*
(disease. Blood 1981;58:849-51.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Jungers P)110.7 (, Dougados M, Pelissier C, et al. Influence of oral)]TJ
0 Tc 2.1381 -1.25 Td
(contraceptive therapy on the activity of systemic lupus )Tj
T*
[(erythematosus. )54.9 (Arthritis Rheum 1982;25:618-23.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Sanchez-Guerrero J, Karlson EW)91.7 (, Liang MH, Hunter DJ, Speizer)]TJ
0 Tc 2.175 -1.25 Td
(FE, Colditz GA. Past use of oral contraceptives and the risk of)Tj
T*
[(developing systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1997;40:804-8.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (Blumenfeld Z, Shapiro D, Shteinber)17.8 (g M, )54.8 (A)74.2 (vivi I, Nahir M.)]TJ
2.175 -1.25 Td
(Preservation of fertility and ovarian function and minimizing)Tj
T*
(gonadotoxicity in young women with systemic lupus erythematosus)Tj
T*
[(treated with chemotherapy)64.9 (. Lupus 2000;9:401-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Cruz OVP)110.7 (, )54.8 (Ariza R, Banuelos R, Jara LJ, Miranda JM. Ovarian)]TJ
0 Tc 2.175 -1.25 Td
(function preservation with chlormadinone in lupus patients)Tj
T*
[(receiving cyclophosphamide. )54.9 (A)-219.8 (double-blind controlled study)]TJ
T*
[([abstract]. )54.9 (Arthritis Rheum 1999;42 Suppl:S166.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Enns GM, Roeder E, Chan R)59.8 (T)74 (, )54.8 (Ali-Khan Catts Z, Cox )17.7 (V)129.1 (A, Golabi)]TJ
2.175 -1.25 Td
[(M. )54.9 (Apparent cyclophosphamide \(Cytoxan\) embryopathy: a distinct)]TJ
T*
[(phenotype? )54.9 (Am J Genet 1999;86:237-41.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Matsukawa )36.9 (Y)129.1 (. Successful child bearing during intravenous)]TJ
2.175 -1.25 Td
(cyclophosphamide therapy in a patient with systemic lupus )Tj
T*
(erythematosus. Br J Rheumatol 1997;37:342-3.)Tj
-2.175 -1.25 Td
[(17.)-875 (Kirshon B, )17.7 (W)79.8 (asserstrum N, )17.7 (W)39.8 (illis R, Herman GE, McCabe ERB.)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(T)69.7 (eratogenic ef)17.7 (fects of first-trimester cyclophosphamide therapy)64.8 (.)]TJ
0 Tc T*
(Obstet Gynecol 1988;72:462-4.)Tj
-2.175 -1.25 Td
[(18.)-875 (Nguyen )17.7 (T)69.8 (an Lung R, Cranier M, Gaudry C, Kourilsky O.)]TJ
2.175 -1.25 Td
(Cyclophosphamide during pregnancy: a safe prescription [in)Tj
T*
(French]. J Gyn Obstet Biol Reprod 1995;24:314-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (T)69.7 (albot SF)79.7 (, Main DM, Levinson )54.8 (AI. )17.7 (W)79.7 (egener)-37 (\222)55.1 (s granulomatosis: first)]TJ
0 Tc 2.175 -1.25 Td
[(report of a case with onset during pregnancy)64.9 (. )54.8 (Arthritis Rheum)]TJ
T*
(1984;27:109-12 .)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Fields CL, Ossorio MA, Roy )17.7 (TM, Bunke CM. )17.7 (W)79.7 (egener)-37 (\222)55.1 (s )]TJ
0 Tc 2.175 -1.25 Td
[(granulomatosis complicated by pregnancy)64.9 (. )54.8 (A)-219.8 (case report. J Reprod)]TJ
T*
(Med 1991;36:463-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Luisiri P)110.7 (, Lance NJ, Curan JJ. )17.7 (W)79.7 (e)-0.1 (gener)-37 (\222)55.1 (s granulomatosis in )]TJ
0 Tc 2.175 -1.25 Td
[(pregnancy)64.9 (. )54.9 (Arthritis Rheum 1997;40:1354-60.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger)]TJ
0 Tc 2.175 -1.25 Td
[(T)79.8 (A. Pregnancy outcome in women with systemic lupus )]TJ
T*
(erythematosus treated with immunosuppressive drugs. J Rheumatol)Tj
0 Tw T*
[(1993;20:1)36.9 (152-7.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:12)Tj
0 Tw -45.7952 -0.0313 Td
(2576)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 59.08 407.5 -10.83 re
f*
0.5 w
103.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
78 0 obj
<>
endobj
114 0 obj
<>
endobj
42 0 obj
<>
endobj
40 0 obj
<>
endobj
49 0 obj
<>
endobj
48 0 obj
<>
endobj
73 0 obj
<>stream
HdVpTs͋(lb^XG.